Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn's Efficacy Signals [Yahoo! Finance]
Palisade Bio, Inc. (PALI)
Company Research
Source: Yahoo! Finance
no typical PDE4-related side effects, providing a safety foundation to move into longer studies. The study showed encouraging PK/PD and early efficacy signals—plasma troughs exceeded the IC90 by day 14, ileal cAMP rose ~41–43%, fecal calprotectin fell by a mean 59% (rebounding after withdrawal), tissue levels were 3x plasma in the ileum and 5x in the colon, and 40% of patients achieved endoscopic response and 40% endoscopic remission (mean SES-CD down 47.5%)—though the cohort was small and single-arm. Management plans to advance into a broader moderate-to-severe luminal Crohn's program, targeting an IND filing in the second quarter and aiming for top-line data by the end of 2027. Interested in Palisade Bio, Inc.? Here are five stocks we like better. Palisade Bio (NASDAQ:PALI) said it generated encouraging safety, pharmacokinetic and early efficacy signals from an open-label Phase 1b study of PALI-2108 in fibrostenotic Crohn's disease, a difficult-to-treat population where pati
Show less
Read more
Impact Snapshot
Event Time:
PALI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PALI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PALI alerts
High impacting Palisade Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PALI
News
- Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile [Yahoo! Finance]Yahoo! Finance
- Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026GlobeNewswire
- Palisade Bio (PALI) was upgraded by Wolfe Research to "strong-buy".MarketBeat
- Palisade Bio (PALI) is now covered by Wolfe Research. They set an "outperform" rating and a $7.00 price target on the stock.MarketBeat
- Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare ConferenceGlobeNewswire
PALI
Sec Filings
- 4/17/26 - Form PRE
- 4/2/26 - Form 8-K
- 3/20/26 - Form 10-K
- PALI's page on the SEC website